Buckeyes - 

Thanks for the comments - whatever the news - the market doesn't like it and took RVXCF to a 52 week low of .16 - how many more PP's for G&A expenses does the CEO think RVX has? Running on empty and going it alone into 2 Phase III trials is  suicidal. As the 'Peter Principal' aptly predicts, our Chairman and CEO has surpassed his level of competency. Are apabetalone and epigenetics far enough along for BP to take this on and move it forward? It would be tragic to see all the development and the FDA BTD get flushed. But here we are - .16 per share and falling. 

Chicagoest